Evidence map›Paper›PMID 22725625›Full record

ReviewBritish journal of pharmacology2012

Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.

K Mahdy Ali, A Wonnerth, K Huber, J Wojta

Registry-linked trialOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in British journal of pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06330844 (Race Based Stress and Empowerment Focused Compensatory Cognitive Training for Mild Cognitive Impairment), which is not on this map. Cited by 116 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
116citing papers in PubMed, 6 pooled it
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06330844 narecruitingnot on this mapstarted 2025, after this paper: background citation

Race Based Stress and Empowerment Focused Compensatory Cognitive Training for Mild Cognitive Impairment

TypeinterventionalSponsorRosalind Franklin University of Medicine and ScienceRan2025 to 2028Enrolled9ConditionsMild Cognitive ImpairmentArmsRace Based Stress and Empowerment Focused Compensatory Cognitive Training for Mild Cognitive Impairment (RBSEF-CCT-MCI), Motivationally Enhanced Compensatory Cognitive Training for Mild Cognitive Impairment (ME-CCT)
3 · Its place in the literature

Who cites it

116 citing papers in PubMed, 6 syntheses or guidelines pooled it, 303 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Multimorbidity patterns among fragility fracture patients aged 50 + years in China and the US.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

56 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

K Mahdy AliDepartment of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
A Wonnerth
K Huber
J Wojta
Medical University of Vienna · ATWilhelminen Hospital · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the first discovery of an inverse correlation between high-density lipoprotein-cholesterol (HDL-C) levels and coronary heart disease in the 1950s the life cycle of HDL, its role in atherosclerosis and the therapeutic modification of HDL-C levels have been major research topics. The Framingham study and others that followed could show that HDL-C is an independent cardiovascular risk factor and that the increase of HDL-C of only 10 mg·L(-1) leads to a risk reduction of 2-3%. While statin therapy and therefore low-density lipoprotein-cholesterol (LDL-C) reduction could lower coronary heart disease considerably; cardiovascular morbidity and mortality still occur in a significant portion of subjects already receiving therapy. Therefore, new strategies and therapies are needed to further reduce the risk. Raising HDL-C was thought to achieve this goal. However, established drug therapies resulting in substantial HDL-C increase are scarce and their effect is controversial. Furthermore, it is becoming increasingly evident that HDL particle functionality is at least as important as HDL-C levels since HDL particles not only promote reverse cholesterol transport from the periphery (mainly macrophages) to the liver but also exert pleiotropic effects on inflammation, haemostasis and apoptosis. This review deals with the biology of HDL particles, the established and future therapeutic options to increase HDL-C and discusses the results and conclusions of the most important studies published in the last years. Finally, an outlook on future diagnostic tools and therapeutic opportunities regarding coronary artery disease is given.

Indexed as

AnimalsCardiovascular DiseasesCholesterol, HDLFibric AcidsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsNiacinRisk Reduction BehaviorCholesterol, HDLFibric AcidsHydroxymethylglutaryl-CoA Reductase InhibitorsNiacin

Identifiers

PMID22725625
PMCPMC3504986
OpenAlexW1535628640

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.